Searcharxiv⌕ Search

arXiv subjects

Jakub Orłowski

Publications and source records attributed to Jakub Orłowski.

2 recordsLinked to original sources

Neuromorphic Silicon Neuron Controller for Adaptive Deep Brain Stimulation in Parkinson's Disease

Parkinson's disease (PD) affects millions worldwide and causes severe motor symptoms. Adaptive deep brain stimulation (aDBS) delivers physiologically informed stimulation that can track fluctuations in PD motor symptoms, enabling more intelligent DBS control. However, most existing aDBS approaches are primarily algorithm- and software-driven, with limited efforts toward circuit realization, particularly low-power and implantable integrated circuits. This paper presents the Silicon Leaky Integrate-and-Fire Deep Brain Stimulation (SiLIF-DBS) controller, a neuromorphic silicon neuron stimulator implemented with metal-oxide-semiconductor (CMOS) technology. For system-level evaluation, a simplified computational model of the SiLIF-DBS controller is derived and embedded within a Parkinsonian cortico-basal ganglia framework for closed-loop validation. The system is driven by beta-band subthalamic nucleus local field potentials (STN-LFPs), with their average rectified value (Beta ARV) used as the control biomarker. Our SiLIF-DBS controller for aDBS suppresses pathological beta activity while consuming only 25% of the power required by open-loop stimulation and achieving a suppression efficiency of $5.85\%$/$μ$W. Overall, our SiLIF-DBS controller achieves strong beta suppression at substantially reduced power, delivering high suppression efficiency that demonstrates it is a viable foundation for low-power implantable aDBS.

cs.AR↗

Disruption of parkinsonian brain oscillations

Deep brain stimulation (DBS) is an advanced surgical treatment for the symptoms of Parkinson's disease (PD), involving electrical stimulation of neurons within the basal ganglia region of the brain. DBS is traditionally delivered in an open-loop manner using fixed stimulation parameters, which may lead to suboptimal results. In an effort to overcome these limitations, closed loop DBS, using pathological subthalamic beta (13--30 Hz) activity as a feedback signal, offers the potential to adapt DBS automatically in response to changes in patient symptoms and side effects. However, clinically implemented closed-loop techniques have been limited to date to simple control algorithms, due to the inherent uncertainties in the dynamics involved. Model-free control, which has already seen successful applications in the field of bioengineering, offers a way to avoid this limitation and provides an alternative method to apply modern control approach to selective suppression of pathological oscillations.

eess.SY↗